# US 2020/0325181 A1 · Modified viral vectors and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0325181 A1
- Document ID: US20200325181A1
- Status: Published application
- Kind: A1
- Application number: 16/911,171
- Filed: 2020-06-24
- Published: 2020-10-15
- Earliest claimed: 2017-12-29
- Assignees: uniQure IP B.V.
- Applicants: uniQure IP B.V.
- Inventors: David Johannes Francois DU PLESSIS
- Web page: https://patentgrep.com/patent/US20200325181A1

## CPC

- C07K 14/005: from viruses
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 2720/00043: viral genome or elements thereof as genetic vector
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14123: Virus like particles [VLP]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to production of parvoviral vectors to produce adeno-associated virus (AAV) for gene therapy. In particular the invention relates to improvements in parvoviral vectors that increase the packaging capacity, production efficiency, and infectivity of AAV virions that is necessary for large scale manufacturing of AAV for clinical purposes.

## Claims

### Claim 1

An insect cell expressing adeno-associated virus (AAV) VP1 protein and AAV VP3 protein, wherein the insect cell does not express AAV VP2 protein.

### Claim 2 (depends on 1)

The insect cell according to claim 1, comprising:
(a) a nucleotide sequence encoding AAV VP1 protein and AAV VP3 protein; and/or
(b) a nucleotide sequence encoding AAV VP1 protein and a nucleotide sequence encoding AAV VP3 protein.

### Claim 3 (depends on 2)

The insect cell according to claim 2, wherein the nucleotide sequence as defined in (a) of claim 2 comprises:
(a) an open reading frame encoding AAV VP1 protein; and
(b) an open reading frame encoding AAV VP3 protein.

### Claim 4 (depends on 1)

The insect cell according to claim 1, comprising a nucleotide sequence encoding adeno-associated virus (AAV) VP2 protein with an inactivated VP2 initiation codon.

### Claim 5 (depends on 1)

The insect cell according to claim 1, further comprising:
(a) a second nucleotide sequence comprising at least one AAV inverted terminal repeat (ITR) nucleotide sequence and at least one nucleotide sequence encoding a gene product of interest;
(b) a third nucleotide sequence comprising a Rep78 or a Rep68 coding sequence operably linked to expression control sequences for expression in an insect cell; and optionally,
(c) a fourth nucleotide sequence comprising a Rep52 or a Rep40 coding sequence operably linked to expression control sequences for expression in an insect cell.

### Claim 6 (depends on 5)

The insect cell according to claim 5, wherein the insect cell comprises:
(a) a first nucleic acid construct comprising (i) nucleotide sequences for AAV VP1 protein and AAV VP3 protein, (ii) the third nucleotide sequence and, optionally, (iii) the fourth nucleotide sequence; and,
(b) a second nucleic acid construct comprising the second nucleotide sequence.

### Claim 7 (depends on 6)

The insect cell according to claim 6, wherein the second nucleic acid construct is an insect cell-compatible vector.

### Claim 8 (depends on 7)

The insect cell according to claim 7, wherein the vector is a baculoviral vector.

### Claim 9 (depends on 5)

A method for producing an AAV in an insect cell, comprising:
(a) culturing an insect cell according to claim 5 under conditions to produce AAV; and optionally,
(b) recovering the AAV.

### Claim 10

A nucleic acid construct, comprising:
(a) a nucleotide sequence comprising an open reading frame encoding adeno-associated virus (AAV) VP1 protein; and
(b) a nucleotide sequence comprising an open reading frame encoding AAV VP3 protein,
wherein the open reading frames encoding the AAV VP1 protein and the AAV VP3 protein are operably linked to expression control sequences for expression in an insect cell, and
wherein AAV VP2 protein cannot be expressed from the nucleic acid construct.

### Claim 11 (depends on 10)

The nucleic acid construct according to claim 10, wherein the open reading frame encoding AAV VP3 protein overlaps with the open reading frame encoding AAV VP1 protein.

### Claim 12 (depends on 10)

The nucleic acid construct according to claim 10, wherein the open reading frame encoding AAV VP3 protein and the open reading frame encoding AAV VP1 protein are transcribed from separate nucleotide sequences.

### Claim 13

An AAV virion produced in an insect cell, the AAV virion comprising in its genome at least one nucleotide sequence encoding a gene product of interest, wherein the at least one nucleotide sequence is not a native AAV nucleotide sequence, and wherein the AAV virion comprises AAV VP1 protein and AAV VP3 protein and does not comprise AAV VP2 protein.

### Claim 14 (depends on 13)

The AAV virion according to claim 13, wherein the at least one nucleotide sequence encoding a gene product of interest is located between two AAV ITR nucleotide sequences.

### Claim 15 (depends on 13)

A pharmaceutical composition, comprising the AAV virion according to claim 13.

### Claim 16 (depends on 15)

A method of treating a disease, comprising administering to a subject in need thereof a pharmaceutical composition according to claim 15.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the disease is selected from the group consisting of Congestive heart failure, intermittent porphyria (AIP), age-related macular degeneration, Alzheimer's disease, arthritis, Batten disease, Canavan disease, Citrullinemia type 1, Crigler Najjar, congestive heart failure, cystic fibrosis, Duchene muscular dystrophy, dyslipidemia, glycogen storage disease type I (GSD-I), hemophilia A, hemophilia B, hereditary emphysema, homozygous familial hypercholesterolemia (HoFH), Huntington's disease (HD), Leber's congenital amaurosis, methylmalonic academia, ornithine transcarbamylase deficiency (OTC), Parkinson's disease, phenylketonuria (PKU), spinal muscular atrophy, paralysis, Wilson disease, epilepsy, Pompe disease, amyotrophic lateral sclerosis (ALS), Tay-Sachs disease, hyperoxaluria 9PH-1), spinocerebellar ataxia type 1 (SCA-1), SCA-3, u-dystrophin, Gaucher's types II or III, arrhythmogenic right ventricular cardiomyopathy (ARVC), Fabry disease, familial Mediterranean fever (FMF), proprionic acidemia, fragile X syndrome, Rett syndrome, Niemann-Pick, and Krabbe disease.
